ICH M7(R3) Maintenance IWG/EWG Work Plan *February 27, 2024*

Topic Adoption date: June 2017

Rapporteur: Dr. Aisar Atrakchi, FDA, United States

Regulatory Chair: N/A

Last Face-to-Face Meeting: Amsterdam, Netherlands, June 2019

1. Key milestones

1.a. Current status of key milestones

The EWG is not Active at this time as Step 4 of ICH process has been completed in 2023.

| Past completion date | Milestone |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Jun. 2014 | ICH M7 was issued as Step 4. |
| Mar. 2017 | ICH-M7 (R1) was issued as Step 4. It contains Appendix 3 (Application of the Principles of the ICH M7 Guideline to Calculation of Compound-Specific Acceptable Intakes). |
| Jul. 2018 | The concept paper of ICH-M7 (R2) is proposed which includes maintenance of ICH-M7 with the 2 nd addendum (application of the Principles of the ICH M7 Guideline to Calculation of Compound-Specific Acceptable Intakes) and Q&A topics proposed based on experience through implementation of ICH-M7. |
| Nov. 2018 | The first Face-to-Face meeting of ICH-M7 (R2) was held in Charlotte, USA |
| Jun. 2019 | The second Face-to-Face meeting of ICH-M7 (R2) was held in Amsterdam, The Netherlands. |
| Jun. 2020 | M7(R2) Q&A reached Step 2a/b on 29 June 2020. |
| Oct. 2021 | M7(R2) 2 nd Addendum reached Step 2a/b on 6 October 2021. |
| Apr. 2022 | M7(R2) Q&A reached Step 3 expert Sign-off 26 Apr 2022. |
| May. 2022 | M7(R2) Q&A reached Step 4 |
| Apr. 2023 | M7(R2) Guideline and Addendum reached Step 4 of ICH process |